Thanks for emailing that article!
Catalyst for a Cure (CFC) is a major collaborative research effort redefining how glaucoma research is conducted.
Launched in 2002, the original team of four CFC investigators has made a significant impact on revealing early mechanisms of retina and optic nerve degeneration in glaucoma. Their findings have redefined our understanding of how glaucoma steals sight and opened avenues for new therapeutic approaches to the disease focused not on ocular pressure, but on stopping neurodegeneration.
Based on the success of the original Catalyst for a Cure research team, Glaucoma Research Foundation has assembled a second team of investigators to speed the pace of discovery. Four additional scientists recruited from prestigious academic centers across the country were chosen for their particular expertise in neuroscience, ophthalmology, biophysics, and biomedical imaging.
Their goal is to develop new, specific and sensitive biomarkers to diagnose and manage glaucoma more effectively. This knowledge could potentially help predict glaucoma in patients who do not yet show symptoms of vision loss as well as help doctors choose the best course of therapy tailored specifically for each patient. Together the discoveries of both “Catalyst for a Cure” teams are accelerating the process of discovery toward new diagnostics and treatments, and ultimately a cure.
Identifying molecular biomarkers for glaucoma promises many possible benefits. A molecular biomarker might have predictive use that could help guide more specific therapy in some glaucoma patients. For example, it might help a glaucoma physician know when to intervene earlier. In addition a good biomarker could be used to demonstrate efficacy of drug activity, potentially accelerating federal approval for glaucoma drugs, particularly those that protect the retina and optic nerve.
Last reviewed on October 29, 2017
This article appeared in the September 2012 issue of Gleams.Subscribe